Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity.
Muller
G W
GW
Celgene Corporation, Warren, New Jersey 07059, USA.
Corral
L G
LG
Shire
M G
MG
Wang
H
H
Moreira
A
A
Kaplan
G
G
Stirling
D I
DI
D006801:Humans; D007700:Kinetics; D008070:Lipopolysaccharides / Q000494:pharmacology; D008214:Lymphocytes / Q000187:drug effects / Q000276:immunology*; D015394:Molecular Structure; D010797:Phthalimides / Q000138:chemical synthesis / Q000494:pharmacology; D011744:Pyrimidinones / Q000138:chemical synthesis / Q000494:pharmacology; D013329:Structure-Activity Relationship; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000138:chemical synthesis* / Q000494:pharmacology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000096:biosynthesis*
D008070:Lipopolysaccharides; D010797:Phthalimides; D011744:Pyrimidinones; D014409:Tumor Necrosis Factor-alpha; D013792:Thalidomide